2 & 3 are tiny drugs. Dexcel may not amount to anything. Vigabatrin is only a 3-year contract and we’re what half-way through the agreement with no launch? Generic oxy will not launch next year even if approved. $70M has no realistic basis whatsoever. Any increase in Adderall will be minimal, but the price of Mikah’s 50% will go up much more. Love how he plays both sides.
News 
Market Data 
Discover 
